RxDoctor Payments Data

Andrew Hilldrup

Family Medicine · Midlothian, VANPI 1104212323

Payments from drug & device makers

$11,110in general payments, 2019–2025

Across 709 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Amgen$842
  • AstraZeneca$823
  • Pfizer$769
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$11,110100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,110 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$247,336
Medicare patients
361
Services billed
4,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$97,934
JanuviaSitagliptin Phosphate67$69,918
RybelsusSemaglutide42$66,344
Repatha SureclickEvolocumab40$50,283
MyrbetriqMirabegron58$45,719
EliquisApixaban60$44,362
JardianceEmpagliflozin31$36,402
XareltoRivaroxaban28$35,994
FarxigaDapagliflozin Propanediol34$33,159
Tresiba Flextouch U-200Insulin Degludec40$28,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$26,723
Xtampza ErOxycodone Myristate24$21,905
Rosuvastatin Calcium565$7,954
EntrestoSacubitril/Valsartan11$7,740
HorizantGabapentin Enacarbil12$5,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,076$164,278123 claims
MerckJanuvia$224$69,91867 claims
PfizerEliquis, Premarin$769$48,42376 claims
Astellas Pharma US IncMyrbetriq$23$45,71958 claims
Boehringer IngelheimJardiance$617$36,40231 claims
Johnson & JohnsonXarelto$24$35,99428 claims
AstraZenecaFarxiga$823$33,15934 claims
GSKTrelegy Ellipta$411$26,72328 claims
NovartisEntresto$132$7,74011 claims
Kowa Pharmaceuticals America, Inc.Livalo$57$5,64414 claims
AbbVieSynthroid$1,803$3,54049 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$81$2,386252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →